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Aims: The Diabetes Attitudes Wishes and Needs 2 (DAWN2) study aims to provide a holistic
assessment of diabetes care and management among people with diabetes (PWD), family
members (FM), and healthcare professionals (HCPs) and explores potential drivers leading to
active management.
Methods: DAWN2 survey over 16,000 individuals (9000 PWD, 2000 FM of PWD, and 5000
HCPs) in 17 countries across 4 continents. Respondents complete a group-specific question-
naire; items are designed to allow cross-group comparisons on common topics. The ques-
tionnaires comprise elements from the original DAWN study (2001), as well as
psychometrically validated instruments and novel questions developed for this study to
assess self-management, attitudes/beliefs, disease impact/burden, psychosocial distress,
health-related quality of life, healthcare provision/receipt, social support and priorities for
improvement in the future. The questionnaires are completed predominantly online or by
telephone interview, supplemented by face-to-face interviews in countries with low inter-
net access. In each country, recruitment ensures representation of the diabetes population
in terms of geographical distribution, age, gender, education and disease status.
Discussion: DAWN2 aims to build on the original DAWN study to identify new avenues for
Contents available at Sciverse ScienceDirect
Diabetes Research
and Clinical Practice
journal homepage: www.elsevier .com/locate/diabresimproving diabetes care.
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1. Introduction
In 2001, the Diabetes, Attitudes, Wishes and Needs (DAWN)
study showed that self-management of diabetes was consid-
ered poor by people with diabetes (PWD) and healthcare
professionals (HCPs). Diabetes-related distress was common
amongst PWD and hampered efforts to self-manage their
condition, but few received psychological treatment [1].
Although recognition by HCPs of emotional problems and
diabetes-specific distress amongst PWD was low, HCPs desired
a better understanding of such issues [2]. Collaboration among
diabetes care providers was identified as an important factor for
improving diabetes outcomes, but interdisciplinary team care
was uncommon [2], and there was some resistance by PWD and
HCPs to the timely initiation of effective therapies [3].
Following DAWN, patient representatives and an interdis-
ciplinary group of diabetes care experts discussed how the
DAWN findings could be translated into improved diabetes
care [4]. The resulting ‘DAWN Call to Action’ [5] encouraged
multiple stakeholders (HCPs, PWD and their family members
[FMs]/carers, payers, policy makers, industry and non-gov-
ernment organisations) to implement person-centred diabe-
tes care, and actively involve PWD in self-management with
support from an interdisciplinary team of HCPs [2].
The DAWN findings support a paradigm shift from an acute
care model to a person-centred, integrated chronic care
model, such as the WHO Innovative Care for Chronic
Conditions framework to diabetes [6]. This model involves
care at three levels: micro, meso and macro, which refer to
individual, healthcare organisation/community, and policy
levels, respectively [6]. Optimal diabetes care is best achieved
by collaboration between PWD, FM, community partners and
healthcare teams that are informed, motivated, prepared, and
able to work together. This collaboration is supported and
influenced by the broader healthcare organisations and
communities, and by the policy environment [6]. Scientific
evidence provides the foundation for the approaches to care
[6], but the PWD perspective is important in informing all
levels of healthcare [7]. PWD have the right to be informed and
educated, to have access to proper diabetes care and optimal
medicine, and not to be discriminated against because of their
condition [8].
It is a decade since the DAWN study highlighted the need
for collaborative action across countries to improve self-
management and psychosocial support. Despite major
advances in collaborative care many PWD still do not achieve
desirable treatment outcomes. The growing burden of diabe-
tes calls for stronger and broader globally-coordinated efforts.
As more countries recognise the effect of diabetes on
population health, and the economic and personal burdens,
we must expand our knowledge to include the diverse social
institutions and cultures of these countries. As our knowledge
has advanced, we have identified gaps in our knowledge of the
role of support from family and community in living with and
caring for PWD. Across nations, there is a pressing need for a
new global translational research initiative that can form the
foundation for measurement-guided multi-stakeholder col-
laboration for the advancement of person-centred diabetes
care world-wide. Thus, it is time for a new DAWN.in partnership with the International Diabetes Federation
(IDF), the International Alliance of Patient Organisations
(IAPO), the Steno Diabetes Center, and a range of other
national, regional and global partners, aims to (a) improve our
understanding of the unmet needs of PWD and their care-
takers, (b) facilitate dialogue and collaboration among all key
stakeholders to strengthen patient involvement and improve
self-management and (c) establish a cross-culturally validat-
ed multi-national survey framework for assessing and
benchmarking psychosocial and educational aspects of
diabetes care delivery. The overall aim is to identify avenues
for improvement at all three levels of care – at the meso and
macro-levels for diabetes care funding and care provision,
and at the micro level for delivery of care. The study explores
how PWD, FMs and HCPs perceive diabetes care and
investigates the value of a person-centred model of diabetes
care that emphasises the needs of the individual in the
context of current chronic care, self-management education
and psychosocial support. This paper describes the study
methodology.
2. Materials and methods
2.1. Study objectives
Within a national and international setting, the predefined
objectives of the DAWN2 study are:
Primary objective:
 To assess potential barriers to and facilitators of active and
successful management of diabetes among PWD, FMs, and
HCPs.
Secondary objectives:
 To establish national benchmarks for health status, quality
of life (QoL), access to self-management education and to
self-care in diabetes.
 To assess the access to, and use and benefit of, support from
healthcare teams, family and friends, communities and
society.
 To explore and pinpoint the most important facilitators and
barriers to person-centred chronic care for each stakeholder
group.
 To identify successes, wishes, needs, preferences and
priorities for change among all key stakeholders in diabetes.
2.2. Study design
DAWN2 is a multinational, interdisciplinary and multi-
stakeholder study designed in February 2011 to examine the
experiences and unmet needs of PWD, FMs, and HCPs (UTN
No: U1111-1123-7509; NCT01507116). DAWN2 has been devel-
oped and overseen by the Global DAWN2 Study Group under
the auspices of the IDF, IAPO and the Steno Diabetes Center
with input from experts from: American Association of
Diabetes Educators, Federation of European Nurses in Diabe-
tes, Primary Care Diabetes Europe, Behavioral Research in
Diabetes Group Exchange, Psychosocial Aspects of Diabetes
Study Group of the European Association for the Study of
Table 1 – Inclusion and exclusion criteria.
Inclusion criteria
 All participants: Internet access at home or convenient
location or able to attend a face-to-face or telephone
interview; informed consent before the start of any
study-related activities
 PWD: Adults aged 18 years diagnosed with diabetes by an
HCP at least 12 months ago (type 1 or type 2; not only during
pregnancy)
 FM: Adults aged 18 years who are not diagnosed with
diabetes, live in the same household with an adult
(18 years) with diabetes (type 1 or type 2; not only
during pregnancy) and are involved in his/her care
 HCP: GPs, PC physicians and internal medicine physicians
who have been in practice for 1 year and who personally
treat 5 adults (18 years) with diabetes per month and
initiate oral medication
 HCP: Diabetes specialists (endocrinologists/diabetologists
or GP/PC physicians/internal medicine physicians with
sub-speciality in diabetes) who have been in practice for
1 year, personally treat 50 adults (18 years) with
diabetes per month and prescribe insulin (may also
prescribe oral medication or other injectable diabetes
medications). Threshold may be adjusted according
to country-specific requirements
 HCP: Other HCPs (diabetes nurses/dietitians/other HCPs)
who have been in their respective professions for
1 year and provide care for 5 adults (18 years) with
diabetes per month
Exclusion criteria
 All participants: Inability to understand and comply with
written and verbal instructions
 PWD: Individuals aged <18 years and/or diagnosed with
diabetes less than 12 months ago and/or diagnosed with
diabetes only during pregnancy
FM, family members; GPs, general practitioners; HCP, healthcare
professional; PC, primary care; PWD, people with diabetes.
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centred diabetes care. Fieldwork began in March 2012.
2.3. Ethical considerations
In each country, the study is being conducted in accordance
with the relevant ethical requirements, following regional/
national/local guidelines relating to the conduct of non-
interventional studies and uses guidelines of the International
Chamber of Commerce/European Society for Opinion and
Marketing Research [9], the Council of American Survey
Research Organizations [10] and Good Pharmacoepidemiology
Practices [11] as a minimum standard.
2.4. Study participants
DAWN2 is being conducted in 17 countries: Algeria, Canada,
China, Denmark, France, Germany, India, Italy, Japan, Mexico,
The Netherlands, Poland, Russia, Spain, Turkey, United
Kingdom (UK) and United States of America (USA). Brazil
was originally included in the study plan, however due to
timing issues, the DAWN2 study in Brazil will be conducted
separately.
The participating countries represent 4 continents –
Europe, Asia, North America, and Africa. Countries volun-
teered for participation in DAWN2, including providing
study funding, mainly to identify ways to enhance diabetes
care and the lives of PWD and their FM. Other countries are
currently applying or planning to apply components of the
DAWN2 study design as part of the wider DAWN network;
however, these research activities are not part of the 17-
country DAWN2 study. Overall, the study population
comprises 16,100 participants: 9040 PWD, 2160 FMs and
4900 HCPs. Inclusion/exclusion criteria are presented in
Table 1. Each country’s sample is a minimum of 900
participants: 500 PWD, 120 FMs and 280 HCPs (see Fig. 1).
In the USA, an additional sample of 540 PWD and 120 FMs of
African-American, Hispanic and Asian ethnic origin and 140
HCPs who treat minority populations is included to obtain
adequate numbers for subgroup analyses. In general, the
three participant groups are independent (e.g., participants
in PWD sample are not treated by participants in HCP
sample). However, for the FM sample, some of the 120
participants do live in the same household as individuals
who participated in the PWD survey. The data for these
participants enables linkage between this subset of PWD
and their FMs.
The HCP sample comprises specialist physicians (endocri-
nologists and diabetologists), primary care (PC) providers,
general practitioners (GPs) and internal medicine physicians
(with a sub-speciality in diabetes) and other HCPs (e.g.,
diabetes nurses, dietitians, diabetes educators, counsellors
or physician’s assistants, who vary by country). The sample of
PWD predominantly comprises those with type 2 diabetes
(with quotas for different treatment regimens), but also
includes participants with type 1 diabetes.
The global study sample (and subsample) sizes are
sufficient to achieve more than 80% power for a ‘small’ effect
size (e.g., Cohen’s d = 0.2). National samples of PWD and HCP
were designed to achieve 80% power for a ‘medium’ effect size(e.g., Cohen’s d = 0.5). Minimum national sample size was 120
to achieve 80% power to detect a difference in proportions of
10%. Minimum national subsample size was 80 to permit
effective weighting (especially important when proportional
sampling would generate a smaller subsample that would not
yield a reliable subsample estimate).
2.5. Recruitment methodology
2.5.1. HCPs
In all countries, potential participants are identified primar-
ily from online panels and databases. When necessary,
other sources such as telephone lists and physician
directories are used for recruitment. All potential partici-
pants are invited to take part via email or phone. As with
other DAWN2 survey groups, all participants receive a web-
link to a secure server to enable them to complete the
survey online.
2.5.2. PWD and FMs
Web, telephone and in-person methods relevant to each
country’s situation were applied while trying to maximise
comparability of methodologies and survey populations
across countries.
HCPs
(n=280)
Nurses/dietitians 
and other HCPs (n=80)
*In the USA, additional 540 PWD and 120 FMs recruited to better represent African-American, 
Hispanic and Asian ethnic groups, plus 140 HCPs who work with minority populations.
†Some of the 120 FMs live with PWDs, allowing linkage between this subset of PWD and 
their FMs.
FM: family members; GPs: general practitioners; HCP: healthcare professional; 
PWD: people with diabetes
Endocrinologists/
diabetologists (n=80)
GPs (n=120)
PWDs
(n=500)
FMs
 (n=120)†
Type 2
- insulin treated (n=150)
- non-insulin medication (n=170)
- diet/exercise only (n=100)
Type 1 (n=80)
Participants per country (n=900)*
Fig. 1 – Composition of DAWN2 study population in each country.
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In 11 DAWN2 countries with high internet penetration (USA,
Canada, UK, France, Germany, Italy, Spain, Denmark,
Netherlands, Poland, Japan) a hybrid online and telephone
methodology is used to recruit PWD and FMs. In these groups,
participants are enrolled using web-based recruitment or by
telephone. This recruitment methodology is intended to
ensure the study population in these countries is as
representative as possible of the wider diabetes community
and to address concerns regarding potential bias if the entire
sample were obtained through web-based recruitment.
For the online sample, potential participants are identified
from multiple online panels and databases per country.
Individuals identified from these sources are contacted by
email and invited to participate in the study. Participants
recruited by telephone may complete the survey either by
telephone or online. Depending on their preference, partici-
pants are either sent a web-link via email to complete the
survey online or are interviewed by telephone.
For the telephone sample, potential participants are
identified from a variety of sources (general telephone lists,
proprietary databases, lists from past research, patient
association lists). They are contacted by telephone and, if
eligible, invited to participate in the study. Procedural details
for non-web-based recruitment are country-specific and
comply with local logistics and ethical regulations.
2.5.4. Face-to-face-methodology
In the remaining six DAWN2 countries with lower internet
access (Algeria, China, India, Mexico, Russia and Turkey)
participants are recruited by telephone or face-to-face using
telephone lists, patient association lists, proprietary data-
bases, and hospital and physician directories. Participants
complete the questionnaire via a face-to-face interview.2.6. Questionnaires
The multi-dimensional scientific survey design for DAWN2
was developed by the Global DAWN2 Survey Working Group
according to a person-centred model for chronic illness care
with input from multi-national, multi-disciplinary meetings
involving representatives of all the countries participating in
DAWN2, and patient advocacy and scientific experts from the
collaborating organisations. A summary of the main topics
and subtopics covered by the PWD, FM, and HCP question-
naires is presented in Table 2. The questionnaires were
designed to permit comparison across respondent types
where possible.
The questionnaires incorporate several elements, includ-
ing: items from the original DAWN study (to enable
evaluation of trends in diabetes care over the past decade);
newly developed questions (to investigate areas such as
discrimination and the needs and preferences for better
education and support); and open-ended questions (to
capture the individual stories of the respondents). Some
new questions were developed with inspiration from, or
adapted/modified from existing validated instruments, as
relevant in each case with the originators of the ques-
tionnaires, including the Diabetes Empowerment Scale-
short form (DES-SF) [12,13]; Diabetes Family Behavior
Checklist (DFBC) [14] and the Health Care Climate Question-
naire (HCC) [15]. In addition, several standardised instru-
ments were incorporated into the questionnaires in original
or shortened forms, including: the Problem Areas in
Diabetes-short form (PAID-5) [12–20]; Patient Assessment
of Chronic Illness Care (PACIC) [16,17]; Summary of Diabetes
Self-Care Activities Measure (SDSCA) [21]; WHOQOL-BREF
[22]; EuroQol (EQ-5D) [23]; and the WHO Well-Being Index
(WHO-5) [24].
Table 2 – Summary of main topics and subtopics covered by the PWD, FM, and HCP questionnaires.
Topic Subtopic
PWD FM HCP
Sociodemographics Age; gender; height; weight;
ethnic origin; country-
specific education and
income; country-specific
socioeconomic questions;
work situation; geographical
location; country-specific
region questions
Age; gender; ethnic origin;
country-specific education
and income; country-specific
socioeconomic questions;
work situation; geographical
location; country-specific
region questions
Age; gender; geographical
location; years in practice/
profession; area of speciality/
subspecialty
Diabetes profile Diagnosis; time of diagnosis;
type of treatment received at
diagnosis and currently;
medication/treatment status
(current diabetes treatment,
types of pills, mode of
insulin administration,
number of insulin
injections); hypoglycaemia
(self-treated, severe,
hypoglycaemia awareness);
existing comorbidities/
complications
Diagnosis; time of diagnosis;
type of treatment received at
diagnosis and currently;
medication/treatment status
(current diabetes treatment,
types of pills, mode of
insulin administration,
number of insulin
injections); hypoglycaemia
(self-treated, severe, number
of times received medical
assistance, awareness); type
of diabetes
Patients (%) with type 1/type
2 diabetes; medication/
treatment status (current
diabetes treatment, types of
pills, mode of insulin
administration, number of
insulin injections)
Health and QoL QoL (WHOQOL-BREF); health
status (EQ-5D mobility, self-
care, usual activities, pain/
discomfort, anxiety
depression, VAS Scale);
emotional well-being/mental
health (WHO-5); BMI; weight
QoL (self – WHOQOL-BREF);
emotional well-being/mental
health (self – WHO-5); weight
Patients (%) with clinical
depression
Diabetes impact
and burden
Diabetes distress (PAID);
overall impact; impact on
physical health; personal
relationships; financial
impact; productivity/work/
leisure activities; impact on
emotional well-being;
depression related to
diabetes; dietary restrictions
Diabetes distress (PAID
Family Versions); overall
impact; physical health;
impact on personal
relationships; financial
impact; productivity/work/
leisure activities; impact on
emotional well-being;
depression related to
diabetes; dietary restrictions;
burden of caring
Need for improvement in
dealing with emotions
around diabetes; societal
burden of diabetes
Diabetes control Perceived control;
improvements needed in
HbA1c; blood pressure; lipid
profile/cholesterol; weight
Perceived control;
improvements needed in
HbA1c; weight
HbA1c levels; improvements
needed in weight
Diabetes management Self-management
behaviours (SDSCA including
diet, exercise, blood sugar
testing, feet checking, taking
medication, smoking);
improvements needed
Self-management
behaviours (improvements
needed in diet, exercise,
blood sugar testing/control,
taking medication, dealing
with emotions around
diabetes, weight)
Self-management
behaviours (improvements
needed in: diet, exercise,
blood sugar testing, taking
medication, dealing with
emotions around diabetes,
weight, taking responsibility)
Family and social
support
Non-HCP support behaviours
(modified DFBC); non-HCP
involvement; reasons for
non-involvement; living
situation; family conflict;
overall social support
Non-HCP support behaviours
(modified DFBC); non-HCP
involvement; reasons for
non-involvement; living
situation; family conflict;
split of responsibilities;
overall social support;
assistance with
hypoglycaemia
Importance of family
involvement
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 9 9 ( 2 0 1 3 ) 1 7 4 – 1 8 4178
Table 2 (Continued )
Topic Subtopic
PWD FM HCP
Healthcare support Person-Centred Chronic
Illness Care: (modified
PACIC/HCC: asking about
QoL and medication
problems, patient activation,
listening, goal-setting,
problem-solving, giving
confidence, planning on-
going family/community
support, group
interventions, pro-active
follow-up, care organisation)
Access to medical care/
medical supplies;
accessibility; HCP
assessments (HbA1c, blood
pressure, lipid profile/
cholesterol, weight, feet,
anxiety/depression, diet,
exercise); early diagnosis
Accessing medical care;
discussion/improvement of
prevention activities; early
diagnosis
Person-Centred Chronic
Illness Care (HCPPACIC
items/HCC version: asking
about QoL and medication
problems, patient activation,
listening, goal-setting,
problem-solving, giving
confidence, planning on-
going family and community
support, group
interventions, pro-active
follow-up, overall care
organisation); team care
Access to medical care/
medical supplies;
accessibility; HCP
assessments (HbA1c, blood
pressure, lipid profile/
cholesterol, weight, feet,
depression, eyes)
Practice/provision around:
screening/early detection,
diabetes prevention, HbA1c
lab tests, emotional distress,
structured education
Clinic resources for: Care for
vulnerable groups, individual
counselling, IT-systems for
quality monitoring/
improvement and
coordinated care,
involvement of patients to
improve local care;
healthcare remuneration
system
Role of dietitians/educators
Education and information Education attended and
helpfulness; education,
information and support
relied on, desired;
understanding of
medications
Education attended and
helpfulness; education,
information and support
relied on, desired
Education attended,
resources and referral
options for HCPs; desired
future training; role of
educators and dietitians;
information and support
methods
Workplace, community
and wider environment
Community/societal
improvements (acceptance
healthy eating, exercising,
workplaces, early diagnosis
and treatment)
Discrimination; community
support/activities; virtual
support
Community/societal
improvements (acceptance
healthy eating, exercising,
workplaces, early diagnosis
and treatment, public
awareness, prevention, good
medical care)
Discrimination; community
support/activities; virtual
support; tolerance; diabetes
in the media
Community/societal
improvements (acceptance
healthy eating, exercising,
workplaces, early diagnosis
and treatment, public
awareness, prevention)
Discrimination; Community
support, collaboration,
prevention programmes;
virtual support;
reimbursement
Attitudes and beliefs Illness and treatment beliefs
and attitudes, activation and
empowerment; intentions to
improve self-management;
medication beliefs; insulin
beliefs; willingness to start
medication; fear of
hypoglycaemia; diet and
exercise beliefs
Illness and treatment beliefs
and attitudes, activation and
empowerment, intentions to
improve self-management;
fear of hypoglycaemia;
confidence in dealing with
hypoglycaemia; inspiration
from PWD; understanding of
diabetes
Empathy, perceived
influence on patient self-
management; advocacy for
patients; attitudes to patient
responsibility; role of FMs;
attitudes towards
medications
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Table 2 (Continued )
Topic Subtopic
PWD FM HCP
Wishes and future
needs
Desired future family and
social support; improvement
areas in country/region;
improvements in self-
management
Desired future family and
social support; improvement
areas in country/region
Desired future family and
social support; desired
improvements of
medications; improvement
areas in country/region;
improvements needed in
medical care and
psychosocial support
Personal experiences Open-ended questions
(impactful story about how
to manage diabetes,
challenges, successes,
wishes)
Open-ended questions
(impactful story about living
with someone with diabetes/
involvement in diabetes care
of PWD, challenges,
successes, wishes)
Open-ended questions
(challenges, successes,
wishes)
DFBC, Diabetes Family Behavior Checklist; EQ-5D, EuroQol; FM, family members; HbA1c, glycated haemoglobin; HCC, Health Care Climate
Questionnaire; HCPs, healthcare professions; PACIC, Patient Assessment of Chronic Illness Care; PAID, Problem Areas in Diabetes scale; PWD,
people with diabetes; SDSCA, Summary of Diabetes Self-Care Activities Measure; WHOQOL-BREF, World Health Organization Quality of Life
questionnaire; WHO-5, WHO (five) Well-Being Index.
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English version by leading experts from all participating
countries. The three survey questionnaires in English were
tested further with 16 participants (7 PWD, 3 FMs and 6 HCPs)
from India, Canada, USA, and the UK, to assess whether the
questionnaire content was unambiguous and understandable
and to ensure face validity and acceptability. Questionnaires
were subjected to additional written reviews by people with
type 1 and type 2 diabetes prior to finalisation.
Questionnaires for the three surveys were translated into
the primary language(s) of each participating country by at
least two independent local professional translators who were
native speakers in the relevant local language. These transla-
tions were reviewed by national diabetes experts in each
country to confirm the accuracy and cross-cultural equiva-
lence of the translations. A subset of selected psychometri-
cally validated scales and items intended for scientific
benchmarking within and across countries were back trans-
lated into English by a third independent professional
translator and a review and harmonisation process was
undertaken. This involved the approval by academic experts
and originators of the original scientific scales, as well as PWD,
where feasible. This process also involved multi-national
harmonisation of previously published local language ver-
sions of scientific instruments, including the PAID-5, the
WHO-5, the WHOQOL-Bref and the SDSCA.
2.7. Research questions
The DAWN2 surveys were designed to provide data-driven
guidance relevant for all stakeholders in diabetes and chronic
illness management regarding how diabetes care may be
optimised locally, nationally or internationally at the micro,
meso or macro level within a holistic person-centred chronic
care framework. Key research questions include:
1. How do the participating countries compare in terms of
healthcare processes and outcomes based on the measuresthat are proposed as suitable for benchmarking (e.g.,
established validity and reliability of source measures)?
2. What are the determinants of QoL and psychosocial
adaptation of PWD?
3. What are the determinants of self-management behaviour
by PWD?
4. What are the determinants of HCP delivery of person-
centred diabetes care/support (especially those forms of
care/support that are found to have a major impact on
patient outcomes)?
5. What are the determinants of burden for FMs and family
support for PWD, especially those forms of support that are
found to have a major impact on patient outcomes?
6. What is the current level of access to diabetes education,
how is it provided, and what are the benefits to PWD? What
are the roles of nurses, dietitians and other HCP providers?
7. What are the determinants of medication initiation,
adherence, persistence and intensification?
8. What changes have occurred in the period between DAWN
and DAWN2?
9. What are the key events that have created turning-points in
how people live with and manage diabetes? What individ-
ual and societal changes do survey respondents want?
Numerous additional topics will be addressed, but a full
listing of questions is beyond the scope of this paper.
2.8. Supplementary research
In parallel with the three main surveys, a separate situational
assessment is being performed in each country, comprising
literature research on national guidelines, policies and
activities related to person-centred diabetes care, supplemen-
ted by interviews with a range of different national stake-
holders. These are designed to provide an assessment of the
existing diabetes and chronic care delivery systems in each
country, against which the perceptions of survey respondents
can be compared. Representatives of patient associations,
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contributors to this study component. The situational assess-
ment allows each country to benchmark itself relative to other
countries in relation to health policies, guidelines, healthcare
infrastructures, national programmes, and community struc-
tures related to person-centred chronic illness care, and to
identify concrete opportunities for national improvement
from the DAWN2 survey results.
2.9. Analysis
Survey data are provided to the Principal Investigators of each
country’s national advisory or survey group as descriptive
statistics for all variables for each participant group. To permit
generalisation from the sample to larger populations, individ-
ual weights are provided. These weights are based on
population proportions for each country, as provided by each
country’s survey advisory group, and on publicly available
epidemiological data.
Furthermore, the subset of FMs who live in the same
household as individuals who complete the PWD questionnaire
are linked to one another for analysis. This enables comparison
of the perceptions of provision of practical and emotional care
and support from both members of the dyad and assessment of
the association between the behaviour of support givers and the
impact on support recipients. For non-linked samples, concor-
dance between respondents can be assessed statistically for
items that are identical, but other items can only be compared
numerically (e.g., the percentage of PWD who report engaging in
a behaviour and the percentage of PWD that physicians
estimate to engage in that behaviour).
Publications will use the appropriate statistical tests for a
particular hypothesis and type of data. These include
nonparametric bivariate statistics (e.g., chi-squared test,
Kendall correlation coefficient, Mann–Whitney test, Krus-
kal–Wallis test), parametric bivariate statistics (e.g., analysis of
variance, Pearson correlation) and multivariate tests (e.g.,
logistic regression, ordinary least squares regression, analysis
of covariance).
In addition, psychometric validation of multi-item mea-
sures in each country will be performed to confirm cross-
cultural validity and suitability for clinical and benchmarking
purposes.
3. Discussion
The ‘DAWN Call to Action’ [5] identified strategic areas for the
improvement of diabetes care by focusing on the psychosocial
issues attached to living with diabetes [2,5]. Strategies for
national action to improve access to person-centred diabetes
care, as guided by the first DAWN study, included: (1) raising
awareness of the PWD perspective, (2) empowerment of PWD
through information and education, (3) training of HCPs, (4)
development of innovative tools to deliver PWD support, (5)
improvement of guidelines/policies for person-centred care,
and (6) translational research into delivery of person-centred
diabetes care.
Evidence suggests that substantial progress has been made
within these areas, but there is a need for continuedimplementation of these strategies, including training of
HCPs in person-centred chronic illness care [25,26], new tools
and intervention strategies for improving the psychosocial
care of PWD [2,27], revision of guidelines to include sections on
the self-management and psychosocial aspects of diabetes
care [28–39], and research on psychosocial and person-centred
diabetes care [40].
DAWN2 builds upon a decade of multi-nationally coordi-
nated actions and efforts to improve person-centred care.
Following DAWN, other diabetes surveys have been initiated
to explore psychosocial issues in diabetes, but predominantly
in relation to medical therapy and not addressing FM,
community, or patient organisation perspectives.
The scope of DAWN2 is broad and should further our
understanding of issues in diabetes and person-centred care,
over and above that provided by other diabetes surveys. By
surveying the attitudes, wishes and needs of over 16,000
people from the three stakeholder groups involved in day-to-
day living with and management of diabetes, DAWN2 aims to
provide a unique, comprehensive, systematic perspective on
the facilitators and barriers to achieving optimal person-
centred diabetes care.
The design of the DAWN2 questionnaires should enable
identification of discrepancies between the ‘felt needs’ of PWD
and their ‘perceived needs’ by FMs and HCPs. Comparisons of
the results across countries, within the context of differing
national guidelines, policies and care delivery models, may
identify optimal and sub-optimal national and local models of
care, education and community support. Through the cross-
cultural validation of the multiple scientific measurement
instruments incorporated into the DAWN2 survey, each
country can incorporate mini-DAWN2 surveys into clinic,
local, and regional quality improvement programmes, to allow
for within-country benchmarking.
Comparison of DAWN2 data with those from DAWN allows
for the determination of temporal trends in the profile of
diabetes care and, possibly, whether differences between
these data in countries that participated in both studies reflect
a growing recognition and acceptance of the psychosocial
aspects of diabetes care in the past 10 years.
3.1. Study limitations
Many challenges are associated with conducting DAWN2, the
largest multi-national study of its kind in diabetes, including
how to represent the population within each country
accurately. Since DAWN2 aims to study variations in access
to and consequences of diabetes care, community support and
education within and between countries, samples needed to
be geographically and socio-demographically dispersed in
each country. Therefore, recruiting through a limited number
of centres or clinics, as often done in diabetes surveys for
practical reasons, would not be appropriate for DAWN2 as
results would be biased towards well-resourced clinics.
While populations with internet access may be generally
representative of the total population in some countries,
internet methodology may not be fully representative. Phone
recruitment was used to some extent in all countries to
minimise a systematic bias related to internet use only.
Moreover, weighting of the data from each country to national
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some countries, telephone penetration is poor. While the use
of face-to-face recruitment and interviewing in the DAWN2
study helps overcome this barrier to representativeness, the
expense associated with outreach to rural areas in countries
with broad geographic dispersion makes sampling of all areas
of the country infeasible. In addition, some countries and
regions are not represented, e.g., Indonesia, Thailand, the Arab
countries, sub-Saharan Africa and South America. Thus,
results cannot be generalised to the entire global population
of the three key diabetes stakeholder groups.
4. Conclusions
The original DAWN study identified a major gap between the
psychosocial and educational support needs of PWD, and the
care and support available in developed and less developed
countries. However, despite developments in the field of self-
management education and psychosocial care during the past
decade, too many PWD receive inadequate care and support to
enable them to achieve optimal health and well-being. In
response, DAWN2 seeks to identify possible areas for
improvement and determine the drivers of change to achieve
optimal person-centred diabetes care. DAWN2 has been
designed to facilitate easy translation of the study findings,
including involvement of a broad foundation of multiple
national and international diabetes stakeholders.
As the first major survey of the opinions of FMs of PWD,
DAWN2 aims to achieve a broader humanistic and societal
perspective on the needs of PWD and those caring for them.
Responding to the IDF declaration on patients’ rights and
responsibilities, and including all areas of life with diabetes, it
is hoped that DAWN2 will promote improvements in condi-
tions for PWD. Ultimately, DAWN2 aspires to provide a voice
for PWD and those caring for them, which reflects their unmet
needs.
The DAWN2 study should enable new opportunities for
improving diabetes self-management and QoL, and for
ascertaining the critical drivers of active management as well
as improvement in person-centred diabetes care. These
findings may facilitate innovative efforts by all stakeholders
to improve self-management and psychosocial support in
diabetes.
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